Drug Profile
NVP 1603
Alternative Names: NVP-1603; NVP-1603-1; NVP-1603-1and NVP-1603-2; NVP-1603-2Latest Information Update: 04 Sep 2019
Price :
$50
*
At a glance
- Originator Navipharm
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 21 Aug 2019 Discontinued - Preclinical for Pain in South Korea (PO, Capsule) (NCT03220399)
- 21 Aug 2019 Discontinued - Preclinical for Pain in South Korea (PO, Tablet) (NCT03220399)
- 21 Aug 2019 Navipharm Corporation withdraws a phase I trial prior to enrolment in Healthy volunteers as the company decided to stop the drug development (PO, Tablet, Capsule) (NCT03220399)